HELSINKI – November 02, 2026 -- Stora Enso shareholders will vote on 15 December 2026 on a cross-border partial demerger that would spin the company's Swedish forest assets business into a new, separately listed company, Bergslagets Skogar AB. The Board of Directors recommends approval.

TORONTO – October 31, 2026 -- Blue Moon Metals Inc. (TSXV: MOON; NASDAQ: BMM) has terminated its proposed acquisition of a portfolio of 33 tungsten and antimony projects in the western United States, ending a deal first disclosed in a news release dated August 11, 2026.

Blue Moon and the vendor end the portfolio deal by mutual consent

The private owner and Blue Moon agreed to end the arm's-length transaction under the terms of the letter agreement dated August 10, 2026. The source gives no financial terms for the deal and no reason for the termination.

LAS VEGAS – October 28, 2026 -- MGM Resorts International has amended its Voting Agreement with People Incorporated, capping the investor group's ownership at 29.9% of outstanding shares and binding it to the Board's recommendation on any change of control transaction.

The amendment follows People's withdrawal of its previously announced proposal to acquire MGM Resorts.

Dubai – October 16, 2026 -- Robo.ai Inc. (Nasdaq: AIIO) will cut its Class B share count from 222,116,290 to 8,884,684 through a 1-for-25 reverse stock split effective November 6, 2026, subject to shareholder approval at an extraordinary general meeting (EGM) on October 26.

Singapore – October 16, 2026 -- BUUU Group Limited (Nasdaq: BUUU) will begin trading its Class A ordinary shares on a split-adjusted basis at market open on October 26, 2026, after its board approved a 10-for-1 forward share split. The company says the move is meant to broaden its investor base and improve trading liquidity.

Calgary – October 12, 2026 -- XORTX Therapeutics Inc. has elected to voluntarily delist its common shares from the TSX Venture Exchange (TSXV), ending a dual listing it says no longer justifies its cost. The company will keep its primary listing on Nasdaq (XRTX) and its Frankfurt listing (ANU).

XORTX, a late-stage clinical pharmaceutical company developing therapies for gout and progressive kidney disease, will announce the timing of the delisting in a separate press release.

Calgary – October 12, 2026 -- XORTX Therapeutics Inc. (NASDAQ: XRTX | TSXV: XRTX) has rescinded a US$2.5 million investor relations agreement with IR Agency LLC and recovered the full fee. The company is postponing its marketing push while it exits the TSX Venture Exchange.